- Home
- KPRX vs ADIL Comparison
KPRX vs ADIL Comparison
Compare KPRX & ADIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- ADIL
- Stock Information
- Founded
- KPRX 1998
- ADIL 2010
- Country
- KPRX United States
- ADIL United States
- Employees
- KPRX N/A
- ADIL N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- ADIL Biotechnology: Pharmaceutical Preparations
- Sector
- KPRX Health Care
- ADIL Health Care
- Exchange
- KPRX Nasdaq
- ADIL Nasdaq
- Market Cap
- KPRX 9.2M
- ADIL 7.6M
- IPO Year
- KPRX N/A
- ADIL 2018
- Fundamental
- Price
- KPRX $2.65
- ADIL $0.35
- Analyst Decision
- KPRX Strong Buy
- ADIL Strong Buy
- Analyst Count
- KPRX 1
- ADIL 1
- Target Price
- KPRX $10.00
- ADIL $8.00
- AVG Volume (30 Days)
- KPRX 32.4K
- ADIL 553.7K
- Earning Date
- KPRX 11-07-2025
- ADIL 11-12-2025
- Dividend Yield
- KPRX N/A
- ADIL N/A
- EPS Growth
- KPRX N/A
- ADIL N/A
- EPS
- KPRX N/A
- ADIL N/A
- Revenue
- KPRX N/A
- ADIL N/A
- Revenue This Year
- KPRX N/A
- ADIL N/A
- Revenue Next Year
- KPRX N/A
- ADIL N/A
- P/E Ratio
- KPRX N/A
- ADIL N/A
- Revenue Growth
- KPRX N/A
- ADIL N/A
- 52 Week Low
- KPRX $2.25
- ADIL $0.22
- 52 Week High
- KPRX $4.18
- ADIL $1.30
- Technical
- Relative Strength Index (RSI)
- KPRX 46.53
- ADIL 37.05
- Support Level
- KPRX $2.60
- ADIL $0.34
- Resistance Level
- KPRX $2.80
- ADIL $0.38
- Average True Range (ATR)
- KPRX 0.11
- ADIL 0.02
- MACD
- KPRX -0.01
- ADIL 0.00
- Stochastic Oscillator
- KPRX 21.21
- ADIL 11.67
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.